The antibody-drug conjugate showed a higher objective response rate but failed to meet the primary OS endpoint in patients ...

Gilead Sciences GILD announced that its first-in-class Trop-2-directed antibody-drug conjugate, Trodelvy (sacituzumab ...

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC).

In the study, Trodelvy (sacituzumab govitecan) met its objective of reducing progression-free survival in patients with HR-positive, HER2-negative metastatic breast cancer who received multiple ...

Sacituzumab govitecan, currently indicated in triple-negative breast cancer (TNBC), is undergoing evaluation in NSCLC. In ...

It was a busy week in the biotech sector with lots of regulatory and pipeline updates. Among bigwigs, Gilead Sciences, Inc.

Trodelvy (sacituzumab govitecan-hziy) is a brand-name IV infusion prescribed for certain types of breast cancer in adults. As with other drugs, Trodelvy can cause side effects, such as diarrhea ...

Sacituzumab govitecan failed to improve overall survival in the EVOKE-01 trial, but was well tolerated with no new safety signals. Comprehensive genomic profiling is crucial to address testing ...

Trodelvy (sacituzumab govitecan-hziy) is a prescription drug that’s used to treat certain breast cancers. The drug comes as a powder that’s mixed with liquid to make a solution for intravenous ...

Trodelvy (sacituzumab govitecan-hziy) is a prescription drug used to treat certain breast cancers. Scientists have studied the success rate of Trodelvy and found it to be effective in managing ...

Trodelvy (sacituzumab govitecan-hziy) is a brand-name injection for IV infusion that’s prescribed for certain breast cancers. Trodelvy has interactions with some other drugs. Examples include ...